Global Acute Otitis Media Treatment Market - 2022-2029

Global Acute Otitis Media Treatment Market - 2022-2029

Market Overview

The global acute otitis media treatment market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

Acute otitis media (AOM) is an ear infection that causes pain. It occurs when the middle ear behind the eardrum becomes inflamed and infected. An ear infection (also known as acute otitis media) is an infection of the middle ear, the air-filled space behind the eardrum that houses the ear's tiny vibrating bones.

Market Dynamics

The factors influencing the global acute otitis media treatment market are the increasing research and development and the growing prevalence of acute otitis media.

The increasing research and development are expected to drive the market growth

Acute otitis media (AOM) is a middle ear infection that is the second most common pediatric emergency department diagnosis after upper respiratory infections. Acute otitis media can strike at any age, but it is most common in children aged 6 to 24 months. Approximately 80% of all children will develop otitis media at some point. Between 80% and 90% of all children will develop otitis media with an effusion before reaching school age. Antibiotic treatment for otitis media is debatable and directly related to the subtype of otitis media. Suppurative fluid from the middle ear can spread to nearby locations, causing complications like tympanic membrane (TM) perforation, mastoiditis, labyrinthitis, petrositis, meningitis, and brain abscess, hearing loss, lateral and cavernous sinus thrombosis, and more. As a result, specific guidelines for the treatment of OM have been developed. High-dose amoxicillin is the mainstay of treatment in the United States for children with an established diagnosis of AOM. It is most effective in children under the age of two. In countries like the Netherlands, the initial treatment is watchful waiting, and if the problem persists, antibiotics are prescribed. In patients with otitis media, analgesics such as non-steroidal anti-inflammatory medications like acetaminophen can be used alone or in combination to achieve effective pain control. Due to the risk of prolonged middle ear fluid and its effect on hearing and speech, and the risks of complications, the concept of watchful waiting has not gained full acceptance in the United States and other countries.

Limitations associated with the acute otitis media treatment are expected to hamper the market growth

Antibiotic resistance is becoming more common among pathogens that cause acute otitis media. This finding could lead to changes in the treatment of acute otitis media with antibiotics. Recent antibiotic treatment of acute otitis media, children in daycare facilities, wintertime infections, and acute otitis media in children younger than two years are all risk factors for resistant pathogens. Amoxicillin remains the first-line antibiotic, though a higher dose (80 mg per kg per day) may be necessary to eradicate resistant Streptococcus pneumonia. Second-line options for treatment failure include oral cefuroxime or amoxicillin-clavulanate and intramuscular ceftriaxone. Antibiotic compliance is improved by choosing agents that require less frequent dosing (one or two times per day) and prescribing shorter treatment courses (five days or less). If the patient does not respond to empiric therapy, tympanocentesis can be used to confirm the diagnosis and guide effective treatment.

COVID-19 Impact Analysis

Other airborne-mediated respiratory infections, such as URTI, bronchiolitis, and AOM, decreased due to the measures taken to contain the COVID-19 pandemic. The fear of contracting COVID-19 at the hospital or outpatient clinics also affected the number of children presenting to healthcare facilities for non-urgent complaints like AOM or otitis media with effusion (OME). As a result, there was a decrease in pediatric AOM/OME healthcare utilization. There is a scarcity of data on antibiotic prescription rates for AOM during the COVID-19 pandemic. The COVID-19 era gave healthcare providers a unique opportunity to use treatment guidelines for common childhood infections like AOM. The Choosing Wisely campaigns, which have been seen in over 20 countries, provide information on when antibiotics should be used to avoid unnecessary treatment of viral infections. New toolkits, such as the Canadian College of Family Physicians' Cold Standard toolkit, provide information on using antibiotics in virtual care visits during the COVID-19 era. This campaign encourages clinicians and patients to talk about avoiding overusing antibiotics.

Segment Analysis

Based on drug type, the Antibiotics segment is expected to dominate the market growth

Antibiotic administration is recommended for children older than 6 months of age (who are immunocompetent and without craniofacial abnormalities, tympanostomy tubes, or recurrent AOM) who have a perforated tympanic membrane with purulent drainage, and those with middle-ear effusion and a bulging TM who are moderately or severely ill (i.e., those with high fever [39°C], those with moderate to severe systemic illness). Watchful waiting may be recommended for children who are mildly ill, alert, and have a low-grade fever (39°C) that responds to antipyretics, mild otalgia, and mild or moderate TM bulging. If symptoms worsen or do not improve, antibiotics or a prescription should be filled. If antibiotics are needed, amoxicillin should be given in three divided doses of 45 to 60 mg/kg per day; if twice-daily dosing is used, higher total daily doses of 75 to 90 mg/kg per day are required. If concurrent purulent conjunctivitis, a history of amoxicillin treatment within the previous 30 days, relapse of a recent infection, or nonresponse to amoxicillin, amoxicillin-clavulanate should be considered. If the child has a nonsevere allergic reaction to amoxicillin or penicillin, consider a second-generation (cefprozil or cefuroxime) or third-generation cephalosporin.

Other antibiotics, such as macrolides or clindamycin, can be used, but their efficacy is limited. If oral ceftriaxone is not working, intramuscular or intravenous ceftriaxone may be better. Consider antibiotics for 10 days in children younger than 2 years of age and those with recurrent AOM or AOM with perforated TMs; antibiotics for 5 days in children 2 years of age and older with the uncomplicated disease may be appropriate.

Geographical Analysis

North America region is expected to hold the largest market share in the global acute otitis media treatment market

The increasing prevalence of acute otitis media and the launch of new drugs in this region is expected to drive the market growth.

According to the American Academy of Pediatrics, over 5 million AOM cases occur in children in the United States each year, resulting in over 10 million annual antibiotic prescriptions and over 30 million annual medical visits. In the United States, 70% of all children have one or more AOM attacks before they turn two years old. The incidence of middle ear effusion episodes is approximately 48 percent at 6 months, 79 percent at 1 year, and 91 percent at 2 years, according to a Pittsburgh study that prospectively followed urban and rural children for the first two years of life.

Three preparations were chosen from among the 16 antimicrobials currently approved by the US Food and Drug Administration (FDA) for OM therapy based on studies showing that these drugs achieve sufficient concentrations in middle ear fluid for bactericidal action against the common pathogens in AOM, such as DRSP and beta-lactamase-producing H influenza. Similar studies for the other 13 approved antibiotics have either not been completed or have failed to demonstrate comparable efficacy against resistant bacteria.

Competitive Landscape

The global acute otitis media treatment market is moderately competitive with mergers, acquisitions, and product launches. Some of the key players in the market are Pfizer, Inc., Eli Lilly and Company, Abbott Laboratories, GlaxoSmithKline plc., Medopharm, Alkem Labs, Medopharm, Alkem Labs, Abbott Laboratories, ALK-Abelló, Inc., Lupin Pharmaceuticals, Inc., F. Hoffmann-La Roche AG, Jackson Healthcare

Pfizer, Inc.

Overview: Pfizer Inc., headquartered in Manhattan, New York City, is an American multinational pharmaceutical and biotechnology corporation. The company was founded in New York in 1849.

Product Portfolio: ZITHROMAX is a macrolide antibacterial drug used to treat mild to moderate infections caused by certain bacteria such as adults with acute bacterial sinusitis.

Why Purchase the Report?

Visualize the composition of the global acute otitis media treatment market segmentation by drug class and distribution channel highlighting the key commercial assets and players.

Identify commercial opportunities in global acute otitis media treatment market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of global acute otitis media treatment market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global acute otitis media treatment market report would provide an access to an approx. 45+market data table, 40+figures and 180 pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers